Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer  Svend O Freytag, Yingshu Zhang,

Slides:



Advertisements
Similar presentations
Molecular Therapy - Nucleic Acids
Advertisements

Induction of Shock After Intravenous Injection of Adenovirus Vectors: A Critical Role for Platelet-activating Factor  Zhili Xu, Jeffrey S. Smith, Jie.
Molecular Therapy - Methods & Clinical Development
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Volume 17, Issue 2, Pages (February 2009)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Volume 126, Issue 1, Pages (January 2004)
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 10, Pages (October 2013)
Volume 15, Issue 2, Pages (February 2007)
Volume 9, Issue 3, Pages (March 2004)
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Molecular Therapy - Nucleic Acids
Volume 15, Issue 12, Pages (December 2007)
Molecular Therapy - Oncolytics
Volume 24, Issue 12, Pages (December 2016)
Volume 140, Issue 7, Pages (June 2011)
Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model  Debanjan.
Volume 3, Issue 6, Pages (June 2001)
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
Molecular Therapy - Oncolytics
Volume 19, Issue 3, Pages (March 2011)
Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model  Hao Wu, Di Wen, Ram I Mahato  Molecular Therapy 
Volume 20, Issue 10, Pages (October 2012)
Volume 18, Issue 6, Pages (June 2010)
Volume 29, Issue 6, Pages (December 2008)
Lukkana Suksanpaisan, Rong Xu, Mulu Z
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 10, Pages (October 2013)
Molecular Therapy - Oncolytics
Volume 16, Issue 12, Pages (December 2008)
Molecular Therapy - Oncolytics
Volume 18, Issue 11, Pages (November 2010)
Volume 15, Issue 2, Pages (February 2007)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 20, Issue 12, Pages (December 2012)
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 18, Issue 1, Pages (January 2010)
Volume 18, Issue 1, Pages (January 2010)
Volume 23, Issue 1, Pages (January 2015)
Volume 22, Issue 1, Pages (January 2014)
Volume 14, Issue 1, Pages (July 2006)
Volume 19, Issue 6, Pages (June 2011)
Volume 20, Issue 5, Pages (May 2012)
Suppression of Oncolytic Adenovirus-Mediated Hepatotoxicity by Liver-Specific Inhibition of NF-κB  Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi,
Adenovirus-mediated gene transfer to renal glomeruli in rodents
Volume 6, Issue 3, Pages (September 2002)
Volume 19, Issue 7, Pages (July 2011)
Volume 20, Issue 4, Pages (April 2012)
Molecular Therapy - Nucleic Acids
Volume 16, Issue 1, Pages (January 2008)
Volume 18, Issue 6, Pages (June 2010)
Volume 27, Issue 4, Pages (October 2007)
Molecular Therapy - Oncolytics
Volume 6, Issue 5, Pages (November 2002)
Volume 20, Issue 4, Pages (April 2012)
Volume 16, Issue 4, Pages (April 2008)
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism  Johann Foloppe, Juliette.
Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in Vivo  Maria A. Croyle, Xuan Cheng, Arbans.
Volume 3, Issue 5, Pages (May 2001)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 10, Pages (October 2010)
Volume 15, Issue 2, Pages (February 2007)
Volume 27, Issue 9, Pages (September 2019)
Volume 15, Issue 6, Pages (June 2007)
Presentation transcript:

Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer  Svend O Freytag, Yingshu Zhang, Farzan Siddiqui  Molecular Therapy - Oncolytics  Volume 2, (January 2015) DOI: 10.1038/mto.2015.6 Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Study design. Mice received an injection of saline or Ad5-yCD/mutTKSR39rep-mIL12 on day 1 as described in the text. Animals that were administered the adenovirus also received 5-FC + GCV prodrug therapy for 2 weeks beginning on day 3. Eight animals in each group were sacrificed on days 3, 17, and 78 and CBC, LFT, and histopathology of 12 major organs were examined (five mice/group/time point). IL-12, IFN-γ and adenoviral DNA were quantified in the injected tissue and serum (three mice/group/time point). Molecular Therapy - Oncolytics 2015 2, DOI: (10.1038/mto.2015.6) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 CBC and LFT Each data point represents the mean of five animals ± the standard deviation. WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; ALKP, alkaline phosphatase; ALT, alanine aminotransferase, AST, aspartate aminotransferease. Group 1, 3 × 106 vp intraprostatic; group 2, 3 × 107 vp intraprostatic; group 3, 3 × 108 vp intraprostatic; group 4, 3 × 108 vp intravenous; group 5, saline intraprostatic. Molecular Therapy - Oncolytics 2015 2, DOI: (10.1038/mto.2015.6) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 IL-12 production in mouse versus human prostate epithelial cells. Normal and malignant mouse and human prostate epithelial cells were infected with Ad5-yCD/mutTKSR39rep-IL12 and IL-12 production was measured by ELISA at various times thereafter as indicated. The bars represent the mean of three independent determinations ± SD. Primary cultures of mouse (C57BL/6) and human prostate epithelial cells were used for normal cells. TRAMP-C2 and DU145 cells were used for malignant mouse and human prostate epithelial cells, respectively. Shown are results with Ad5-yCD/mutTKSR39rep-hIL12 (expressing human IL-12). Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse IL-12) gave essentially identical results. Molecular Therapy - Oncolytics 2015 2, DOI: (10.1038/mto.2015.6) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Relative biological potency of mouse versus human IL-12. Human PBMCs were incubated with increasing amounts of IL-12 produced from Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse IL-12) or Ad5-yCD/mutTKSR39rep-hIL12 (expressing human IL-12) and IFN-γ production (left) and cell proliferation (right) were measured 72 hours later. For human IL-12, both laboratory grade and clinical grade adenovirus was examined. Each data point represents the mean of three independent determinations with SD <5%. IFN-γ production with no added IL-12 was 3.2 pg/ml. Molecular Therapy - Oncolytics 2015 2, DOI: (10.1038/mto.2015.6) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions